Exiqon Diagnostics announced today that it now offers KRAS Mutation Analysis
through its CLIA laboratory in California. Cancer treating physicians now have
access to this critical test for their advanced stage colorectal and non-small
cell lung cancer patients who are candidates for anti-EGFR therapy. In the
United States, there are approximately 150,000 new colorectal cancer cases and
over 200,000 lung cancer cases diagnosed each year.1) Many of these patients may
present with advanced disease. In those cases, confirmed KRAS mutation status
is important information for physicians to have when deciding on a treatment
regimen that may contain EGFR-targeted therapies. Published clinical studies
demonstrate that KRAS gene mutations are associated with poor prognosis and
lack of response to EGFR inhibitor therapies.

Recent studies strongly correlate the presence of KRAS mutations in colorectal
cancer patients with lack of response to cetuximab and panitumumab, shorter
progression-free survival (PFS) and shorter overall survival. Studies performed
in NSCLC have shown that mutations in the KRAS gene are strongly predictive of
resistance to tyrosine kinase inhibitors such as gefitinib and eroltinib.

KRAS mutation testing is recommended by the National Comprehensive Cancer
Network (NCCN) before starting EGFR-targeted therapy in both metastatic
colorectal cancer and advanced non-small cell lung cancer patients.2,3).
The American Society of Clinical Oncology (ASCO) favors routine KRAS
mutation testing for patients diagnosed with metastatic colorectal cancer
before initiating anti-EGFR therapies.

“The ability to determine patient response to a particular therapy before it is
administered is critical to prioritizing from an ever increasing list of
potential treatment options”, said Doug Harrington, M.D., Medical Director,
Exiqon Diagnostics. “KRAS Mutation Analysis is an important new diagnostic that
is now available to help physicians stratify their advanced stage colorectal or
non-small cell cancer patients as appropriate candidates for treatment with
EGFR inhibitors. Those patients who have the mutation would most likely not
respond to anti-EGFR drugs and should not be treated with those ineffective and
expensive agents.”

KRAS Mutation Analysis is a welcome addition to the growing molecular
diagnostics test menu available at Exiqon Diagnostics. Additional targeted
molecular profiling assays are currently in development and will be launched
later this year to help physicians more effectively guide treatment decisions.
KRAS testing is just one of the many molecular biomarkers that will be
available to help physicians personalize therapeutic treatment plans.

To learn more about our KRAS Mutation Analysis, please visit
www.exiqondiagnostics.com.

Additional information:
Lars Kongsbak, CEO, tel. +45 45 66 08 88 (cell: +45 40 90 21 01)
R. Erik Holmlin, CCO, tel. +1-714-566-0470
Exiqon Diagnostics Client Services, tel. +1-800-662-6832

Laboratory testing performed by Oncotech, Inc. (dba Exiqon Diagnostics) a
wholly owned subsidiary of Exiqon A/S.

1. American Cancer Society: Cancer Facts and Figures 2008
2. NCCN Clinical Practice Guidelines in Oncology™ Colon cancer. v 2.2009.
Available at: http://www.nccn.org
3. NCCN Clinical Practice Guidelines in Oncology™ Non-small cell lung cancer. v
2.2009. Available at: http://www.nccn.org

About Exiqon:
Exiqon is a biotech company with activities in three business areas where the
company's technologies provide a competitive advantage: Sale of diagnostic
tests (Exiqon Diagnostics), sale of innovative research products for miRNA
research (Exiqon Life Sciences), and in contract research together with
pharmaceutical companies (Exiqon Pharma Services). Exiqon is dedicated to
personalizing the treatment selection for cancer patients. The aim is to
optimize the use of existing medicine and avoid unnecessary and non-effective
treatment. By using molecular diagnostic tests that analyze the genetic profile
of each patient's tumor, treatment selection can be optimized for individuals.
Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon
already markets diagnostic tests that based on fresh tumor tissue enable
doctors to test whether their patients are resistant to one or more of the
chemotherapies offered to treat these patients and help them select an
efficacious treatment. Exiqon's new molecular diagnostic products are based on
the LNA™ technology that enables testing on fixed tissue. Launch of the first
molecular diagnostic product was announced in December 2008. A number of new
products will follow in the years ahead. Using the LNA™ technology is what has
allowed Exiqon to establish a position for itself as one of the market's
leading providers of research products for gene expression analysis. These
research products are used by university scientists and in the pharmaceutical
industry around the world to make groundbreaking discoveries about the
correlation between gene activity and the development various diseases. Exiqon
is also collaborating with pharmaceutical companies in their effort to develop
new medicines based on biomarkers (Personalized Medicine). Exiqon has more than
200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as
a biotech company (Small Cap+). Exiqon is financed until expected breakeven in
2011.

See full press release in the attached PDF.

press_release_uk_kras_final_090511.pdf